Tagged with investment

Serbia Ana Grujovic, executive director of the Swiss-Serbian Chamber of Commerce (SSCC) who has been overseeing Swiss-Serbian business relations since 2014, explains the successful progression of the Chamber since its establishment, the traits that characterize the Serbian market, and the positive indicators for investors looking to explore operations along the Danube.…

Serbia Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession. Where does Genezis stand in 2017 and what is keeping you busy at the moment? “The Serbian…

Serbia Founder and general director of INNventa, Goran Orlic, discusses the rationale behind establishing his own company that continues to double revenues year on year. He highlights the company’s fundamental role in providing innovative solutions to Serbian patients, pharmacists and doctors. Finally, he discusses investment opportunities in the Balkans, underlining the…

Serbia Claude Broudic, general manager for Servier in Serbia, highlights the potential for business in the country, Servier’s projects for expansion in the Balkans, and the skills needed to put together a good pharma team. What were your priorities when you took over as general manager of Servier Serbia? “When looking…

Lithuania Leonas Kalėtinas, executive director at the Lithuanian Innovative Pharmaceutical Industry Association (IFPA), explains the main dynamics impacting the innovative pharmaceutical industry in the country as well as some initiatives developed in collaboration with the national government to continue driving the Lithuanian pharmaceutical sector moving forward. In 2014, the industry signed…

Serbia Predrag Lukic, general manager of Amicus, a new and exciting bridging service for MNCs looking to expand into Serbia and the Balkans, reveals the keys to accessing the region and how best to take advantage of the professional talent pool in Serbia. Through careful study of the market and by…

UK UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam from London following Brexit. Following the Brexit vote, the UK is already seeing problems in filling senior positions at life…

Brazil Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s product portfolio and the region’s healthcare needs as well as the opportunities it entails for the company and Latin America’s…

Serbia Martin Knapp, managing director of the German Chamber of Commerce in Serbia, highlights how Serbia can further develop a more investment-friendly environment and the progress that the country has already made in this regard. Mr. Knapp, it is your second tenure as the Director of AHK in Serbia. What makes…

Lithuania Mantas Katinas, general manager at Invest Lithuania, discusses the country’s strengths, how it can become an attractive destination for Foreign Direct Investment (FDI) and the commitment of the agency towards developing a proper ecosystem for life sciences in Lithuania. Mr. Katinas, you worked in the telecoms industry before joining Invest…

Poland Jakub Szulc, director of life sciences at EY Poland, discusses the exciting opportunities that exist within the healthcare sector in the flourishing Polish economy and the overriding need to increase healthcare spending as the nation prepares for demographic changes in the future. Furthermore, he highlights the innovative services EY provides…

Japan Osamu Nagayama, president of the Japan BioIndustry Association (JBA) and chairman and CEO of Chugai Pharmaceutical, discusses Japan’s footprint in biologics and how mergers between Japanese pharma companies, thereby creating larger R&D funding pools, could hold the key to future success in the biotechnology field. Can you begin by introducing…